Study S001427

Semaglutide 2.4mg for Low Responders After Bariatric Surgery

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06287307
Acronym: SEABAR
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: DOUBLE
Status: UNKNOWN
Enrollment: 152
Start: 2024-05
Primary completion: 2026-02
Lead sponsor: Zuyderland Medisch Centrum
Conditions: Obesity; Obesity, Morbid; Weight Gain
Interventions: OTHER:Placebo; DRUG:Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Weight change from start study at 3 months post operative until 15 months later [15 months]
Difference between placebo group and treatment group in weight change [15 months]

Linked records (7)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0013102	Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. Rubino D, JAMA	2021	Randomized trial	PMID 33755728 DOI	registry reference BACKGROUND:33755728
R0023399	Once-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding JPH, The New England journal of medicine	2021	Randomized trial	PMID 33567185 DOI	registry reference BACKGROUND:33567185
R0023506	Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. Wadden TA, JAMA	2021	Randomized trial	PMID 33625476 DOI	registry reference BACKGROUND:33625476
R0008379	Semaglutide as a promising antiobesity drug. Christou GA, Obesity reviews : an official journal of the International Association for the Study of Obesity	2019	Other trial	PMID 30768766 DOI	registry reference BACKGROUND:30768766
R0027024	A Comparison of New Pharmacological Agents for the Treatment of Obesity. Nuffer W, The Annals of pharmacotherapy	2016	Other trial	PMID 26887340 DOI	registry reference BACKGROUND:26887340
R0027740	Management of obesity. Bray GA, Lancet (London, England)	2016	Narrative review	PMID 26868660 DOI	registry reference BACKGROUND:26868660
R0013881	User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Shaefer CF, Postgraduate medicine	2015	Narrative review	PMID 26371721 DOI	registry reference BACKGROUND:26371721